Rotarex thrombectomy combined with drug-coated balloon for femoropopliteal artery in-stent restenosis: 3 years follow up results

doi:10.3969/j.issn.1006-7795.2021.05.022

Abstract

Abstract: Objective To evaluate the effectiveness and safety of Rotarex thrombectomy combined with drug-coated balloon(DCB) for treatment of femoropopliteal artery in-stent restenosis(FP-ISR). Methods From June 2016 to July 2017, 32 FP ISR patients received Rotarex thrombectomy combined with DCB, which were followed up for 3 years. The primary endpoint was primary patency of the target lesion and freedom from clinically-driven target lesion revascularization (CD-TLR) at 3 years. The secondary endpoint was the rate of major adverse limb events (MALE), amputation and mortality. The primary functional endpoint was assessed by Walking Impairment Questionnaire (WIQ). Results Technical and procedural success was achieved in all 32 patients, 27(84.4%) patients completed 3 years follow-up. Mean ABI was 0.45±0.14 at baseline and 0.81±0.10 at 3 years (P<0.05). The WIQ score was 30.45±21.14 at baseline and 51.32±27.92 at 3 years (P<0.05). The Kaplan-Meier estimate of the primary patency rate at 3 years was 81.5%, freedom from CD-TLR rate at 3 years was 85.2%. Conclusion Rotarex thrombectomy combined with DCB for treatment of FP ISR is safe and effective, the medium and long-term results are satisfactory.

Key words: femoropopliteal artery disease, in-stent restenosis, Rotarex thrombectomy, drug-coated balloon

CLC Number:

R654.4

Liao Chuanjun, Song Shenghan, Zhang Wangde. Rotarex thrombectomy combined with drug-coated balloon for femoropopliteal artery in-stent restenosis: 3 years follow up results[J]. Journal of Capital Medical University, 2021, 42(5): 836-840.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.05.022

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I5/836

References

[1] Levin S R, Arinze N, Siracuse J J. Lower extremity critical limb ischemia: A review of clinical features and management[J]. Trends Cardiovasc Med, 2020, 30(3):125-130.
[2] Rooke T W, Hirsch A T, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2011, 58(19): 2020-2045.
[3] Jaff M R, White C J, Hiatt W R, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease(TASC II): the TASC Steering Comittee[J]. Ann Vasc Dis,2015,8(4):343-357.
[4] Dohi T, Iida O, Soga Y, et al. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions[J]. J Vasc Surg,2014,59(4):1009-1015.
[5] Shishehbor M H. Endovascular treatment of femoropopliteal lesions: so many options, little consensus[J]. J Am Coll Cardiol,2015,66(21):2339-2342.
[6] Kim W, Choi D. Treatment of femoropopliteal artery instent restenosis[J]. Korean Circ J, 2018,48(3):191-197.
[7] Krankenberg H, Tübler T, Ingwersen M, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized Femoral Artery In-stent Restenosis (FAIR) trial[J]. Circulation,2015,132(23):2230-2236.
[8] Kinstner C M, Lammer J, Willfort-Ehringer A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial[J]. JACC Cardiovasc Interv,2016,9(13):1386-1392.
[9] Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis[J]. J Am Coll Cardiol,2012,60(18):1739-1742.
[10]Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study[J]. J Endovasc Ther, 2014,21(1):1-8.
[11]Virga V, Stabile E, Biamino G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up[J]. JACC Cardiovasc Interv,2014,7(4):411-415.
[12]Dippel E J, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITEISR trial (EXCImer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis). JACC Cardiovasc Interv,2015,8(1 pt A):92-101.
[13]Schmidt A, Zeller T, Sievert H, et al. Photo ablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study[J]. J Endovasc Ther, 2014,21(1):52-60.
[14]Liao C J, Song S H, Li T, et al. Combination of rotarex thrombectomy and drug-coated balloon for the treatment of femoropopliteal artery in-stent restenosis[J]. Ann Vasc Surg, 2019, 60:301-307.
[15]Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting[J]. J Am Coll Cardiol,2012,59(1):16-23.
[16]Qato K, Conway A M, Mondry L, et al. Management of isolated femoropopliteal in-stent restenosis[J]. J Vasc Surg, 2018,68(3):807-810.
[17]Ho K J, Owens C D. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis[J]. J Vasc Surg, 2017,65(2):545-557.
[18]Indolfi C, Stabile E, Perrino C, et al. Mechanisms of restenosis after angioplasty and approach to therapy[J]. Int J Mol Med, 1998, 2(2):143-148.
[19]Grotti S, Liistro F, Angioli P, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study[J]. J Endovasc Ther, 2016,23(1):52-57.
[20]Murata N, Takahara M, Soga Y, et al. Drug-eluting stent vs percutaneous transluminal angioplasty for treatment of femoropopliteal in-stent restenosis: results from a retrospective 1-year multicenter study[J]. J Endovasc Ther,2016,23(4):642-647.
[21]Mehrotra S, Paramasivam G, Mishra S. Paclitaxel-coated balloon for femoropoplitral artery disease [J]. Curr Cardiol REP, 2017, 19(2): 10.